Results 161 to 170 of about 25,404,132 (265)

Statement on the relevance of the groundwater metabolite RH-2651 in the assessment of confirmatory data on the active substance tebufenozide. [PDF]

EFSA J, 2021
European Food Safety Authority (EFSA).
europepmc   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Misspecified proportional hazard models and confirmatory analysis of survival data

, 2001
Confirmatory analysis, Empirical process, Interim analysis, Misspecification, Proportional hazard ...
Parner, Erik T., Keiding, Niels
core   +1 more source

Evaluation of confirmatory data following the Article 12 MRL review for quinmerac. [PDF]

EFSA J
European Food Safety Authority (EFSA), Bellisai G, Bernasconi G, Castellan I, Del Aguila M, Ferreira L, Leuschner R, Mioč A, Szot M, Tiramani M, Verani A.   +10 more
europepmc   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Evaluation of confirmatory data following the Article 12 MRL review for cycloxydim and modification of the existing MRLs for escaroles, land cresses and cresses. [PDF]

EFSA J
European Food Safety Authority (EFSA), Bellisai G, Bernasconi G, Castellan I, Del Aguila M, Ferreira L, Leuschner R, Mioč A, Szot M, Tiramani M, Verani A, Lawal AI.   +11 more
europepmc   +1 more source

Spatial and single‐nuclei transcriptomics reveals idiosyncratic and generic patterns in papillary and anaplastic thyroid cancers

Molecular Oncology, EarlyView.
Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur, Joel Rodrigues Vitória, Manuel Saiselet, Ligia Craciun, Denis Larsimont, Anne Lefort, Frédérick Libert, Carine Maenhaut, Sabine Costagliola, Maxime Tarabichi, Mirian Romitti, Vincent Detours   +11 more
wiley   +1 more source

Evaluation of confirmatory data following the Article 12 MRL review for isoxaben. [PDF]

EFSA J
European Food Safety Authority (EFSA), Bellisai G, Bernasconi G, Carrasco Cabrera L, Castellan I, Del Aguila M, Ferreira L, Greco L, Leuschner R, Mioč A, Nave S, Reich H, Ruocco S, Scarlato AP, Szot M, Theobald A, Tiramani M, Verani A, Zioga E.   +18 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Peer review of the pesticide risk assessment for the active substance bifenazate in light of confirmatory data submitted. [PDF]

EFSA J
European Food Safety Authority (EFSA), Álvarez F, Arena M, Auteri D, Leite SB, Binaglia M, Castoldi AF, Chiusolo A, Colagiorgi A, Colas M, Crivellente F, De Lentdecker C, De Magistris I, Fait G, Ferilli F, Santonja GG, Gouliarmou V, Ippolito A, Istace F, Kardassi D, Kienzler A, Lanzoni A, Lava R, Leuschner R, Linguadoca A, Romano ML, Louisse J, Lythgo C, Magrans O, Mangas I, Mazzega S, Mioč A, Miron I, Molnar T, Padovani L, Padricello V, Panzarea M, Parra Morte JM, Rizzuto S, Santos M, Serafimova R, Sharp R, Szentes C, Theobald A, Tiramani M, Vianello G, Villamar-Bouza L.   +46 more
europepmc   +1 more source